Rexahn Pharma said that the patent covers neurotherapeutic pharmaceutical formulation for cefazoline sulfone, cefazoline sulfoxide, ceftriaxone sulfoxide, and ceftriaxone sulfone for treating neurological disease and behavioral and cognitive disorders.
It also covers several novel compounds.
Rexahn Pharma president Rick Soni said that new patent coverage for these cefazolin and ceftriaxone groups broadens their CNS-related portfolio.